Abarelix

CHEMBL1252 Phase 4 अनुमोदित Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1416.1 g/mol
LogP
3.7
Phase
4

A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.

आणविक भार

1416.1000 g/mol

LogP

3.70

TPSA

425.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1

Molecular Formula

C72H95ClN14O14

HBD / HBA

13 / 16

घूर्णनीय बंधन

38

भारी परमाणु

101

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.

Yes, Abarelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1252. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16131215. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.